Making Medicines affordable.

News Room

Press Releases

Media Kit

Press Releases

2005

PRESS RELEASE: 9 December 2005

Greg Perry, Director General of EGA, announced in Paris that biosimilars, the next generation of affordable medicines, are no longer a distant dream, but rather a soon to be realised reality.

PRESS RELEASE: 10 November 2005

Greg Perry, Director General of the EGA has called for a sweeping review of the patent system to eliminate abuse and to ensure a more ethical use of the world’s technological heritage.

PRESS RELEASE: 13 October 2005

Greg Perry, Director General of EGA, speaking to journalists in Finland today, called upon “all sectors to work together” to ensure equitable access to medications for all EU citizens.

PRESS RELEASE: 5 October 2005

Greg Perry, Director General of EGA, stressed today that the “devil is in the detail” when it comes to ensuring the success of the new medicines legislation. The key lies in avoiding a labyrinth of potential pitfalls ...

PRESS RELEASE: 8 September 2005

“This Regulation will provide a better environment with stronger safeguards against abuse than similar legislation in the United States”, says Greg Perry, Director General of the EGA.

PRESS RELEASE: 2 September 2005

On September 7th the European Parliament will vote in First Reading on an important piece of legislation designed to provide better medicines for children in the EU...

POLICY RECOMMENDATION: 29 August 2005

Everybody wants better medicines for children. The importance of ensuring the proper uses and establishing safe doses of adult medicines for children is impossible to overstate...

PRESS RELEASE: 13 July 2005

Only one week after the European Parliament rejected patents on software, the Environment Committee narrowly voted to adopt a 6-month patent/SPC extension for pharmaceuticals ...

JOINT PRESS RELEASE: Kabul, 5 July 2005

• Public-private partnership equips Afghani population to produce safe and effective generic medicines.
• Medicines production equipment donated by EGA arrives in Kabul

PRESS RELEASE: 20 June 2005

“The EU’s pricing and reimbursement systems for pharmaceutical products are hindering competition in the sector and interfering with the creation of optimum conditions for delivering affordable quality healthcare in the EU”.

PRESS STATEMENT: 16 June 2005

NEWS ITEM: 10 June 2005

EGA joins debate on “Today and Tomorrow of the Polish Generic Medicines Industry in the Enlarged EU”

NEWS ITEM: 9 June 2005

Discussions focus on implementation of the new EU pharmaceutical legislation and its implications on access to cost-effective generic medicines in Europe.

PRESS RELEASE: 27 May 2005

The EGA has insisted today on the need to follow sound science when laying out the guidelines for “biogeneric” medicines in Europe. The EGA calls on EU medicines authorities to ensure the full participation of the biogeneric industry in all relevant debates.

PRESS RELEASE: 26 April 2005

The Rapporteur has missed an excellent opportunity to turn the Commission's proposal into a win-win situation for healthcare systems, taxpayers and—more importantly—for children.

PRESS RELEASE: 21 April 2005

Co-organised by EGA and the Association of Bulgarian Pharmaceutical Manufacturers (ABPhM) in an on-going effort to help integrate the eastern European countries into the fabric the EU...

PRESS STATEMENT: 11 March 2005

In a statement delivered at the EMEA’s 10th Anniversary Conference in London today, EGA Director General Greg Perry underscored the important new relationship developing between the agency and generic medicines producers

EGA NEWS ITEM: 2 March 2005

Mr Phillip Whitehead, MEP and Chairman of the Committee on Internal Market & Consumer Protection, told MEPs and the EGA Board of Directors in the European Parliament that “We are thankful to the generic medicines industry for their contribution to bringing down pharmaceutical prices.”

PRESS RELEASE: 3 February 2005

Creating the proper competitive and legal environment is essential for the industry to continue meeting the challenge of providing high volumes of cost-effective generic equivalents to European healthcare systems.

The EGA

“In an era when increasing demands are being made on Europe’s healthcare services, generic medicines provide a major benefit to society as they ensure patient access to quality, safe and effective medicines while reducing the cost of medicinal care.”

The EGA is the official representative body of the European generic pharmaceuticals industry, which is at the forefront of providing high-quality affordable medicines to millions of Europeans while stimulating competitiveness and innovation in the pharmaceutical sector.

The EGA represents over 500 companies and their subsidiaries from greater Europe, and over 100,000 jobs. Generic medicines save €18 billion each year for health care systems and patients.

For further information: